[123I]-Iodometomidate

N/A

Report date: 2025/12/01 17:16:58

Base Information

Drug Name[123I]-Iodometomidate
Drug Alias Name[123I]IMTO
ClassificationSmall moleculesDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agent +[5
Mechanisms of ActionSteroid 11-beta-hydroxylase inhibitorsCytochrome P450 11B2 inhibitors
TargetsCytochrome P450 11B2Steroid 11-beta-hydroxylase
Therapy Area/IndicationsAdrenal Gland NeoplasmsAdrenocortical Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Wurzburg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Würzburg
Active IndicationsN/A
Inactive IndicationsAdrenal Gland NeoplasmsAdrenocortical Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A